Jin Rong Jie·2025-12-25 02:13Group 1 - Sanofi announced an agreement to acquire Dynavax Technologies for approximately $2.2 billion in cash, with the deal approved by Dynavax's board [1] - The acquisition price is set at $15.50 per share, representing a 39% premium over Dynavax's closing price of $11.13 on December 23 [1] - The transaction is expected to be completed in the first quarter of 2026 and will be funded using Sanofi's existing cash reserves, with no impact on its 2025 financial performance [1] Group 2 - This acquisition marks Sanofi's second vaccine-related purchase in 2025, following the $1.5 billion acquisition of UK biotech company Vicebio and a potential $9.5 billion deal for BluePrint Medicines [2] - The move aims to diversify Sanofi's business and reduce reliance on its flagship asthma drug Dupixent [2] - The backdrop of this acquisition includes significant changes in U.S. vaccine policy, with criticism from U.S. Health Secretary Robert Kennedy leading to budget cuts for vaccine research and changes in CDC leadership [2]